Antineoplastic agent, Phosphatidylinositol 3-kinase (PI3K) inhibitor Medicines in UAE
183 medicines available
About Antineoplastic agent, Phosphatidylinositol 3-kinase (PI3K) inhibitor Medicines
This page lists all Antineoplastic agent, Phosphatidylinositol 3-kinase (PI3K) inhibitor medicines available in UAE pharmacies.
Click on any medicine name to view detailed information including uses, dosage, side effects, and availability.
Complete List of Antineoplastic agent, Phosphatidylinositol 3-kinase (PI3K) inhibitor Medicines
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe atopic dermatitis in adults and pediatric patients 12 years and older
Adult dose: | 100 mg once daily; may be adjusted ...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe atopic dermatitis in adults and pediatric patients 12 years and older who are candidates for systemic therapy
Adult dos...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe atopic dermatitis in adults and pediatric patients 12 years and older who are candidates for systemic therapy
Adult dos...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe atopic dermatitis in adults and pediatric patients 12 years and older who are candidates for systemic therapy
Adult dos...
Class: | Bruton's tyrosine kinase (BTK) inhibitor
Use: | Treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); also indicated for mantle cell lymp...
Class: | Bruton's tyrosine kinase (BTK) inhibitor
Use: | Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and for the treatment of adult patie...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myeloid leukemia (CML) in adults with Philadelphia chromosome-positive (Ph+) CML who have had prior therapy and are resistant or intole...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with chronic myeloid leukemia (CML) in chronic phase with the Philadelphia chromosome-positive (Ph+) mutation, particularly in t...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GISTs) with a mutation in the KIT gene, specifically for those with PDG...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of advanced renal cell carcinoma (RCC) after one prior therapy
Adult dose: | Initial dose of 5 mg taken orally twice daily; may be adjusted base...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors;...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more TNF inhibitors; also approved for the t...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of adult patients with chronic myeloid leukemia (CML)
Adult dose:| 400 mg orally once daily with food; dose adjustments may be required based on r...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myelogenous leukemia (CML) in adults with resistance or intolerance to prior therapy
Adult dose: | Initial dose is 500 mg once daily;...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myelogenous leukemia (CML) in adults with Philadelphia chromosome-positive (Ph+) disease
Adult dose: | Initial dose of 500 mg once da...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myelogenous leukemia (CML) in adults with resistance or intolerance to prior therapy
Adult dose: | 400 mg orally once daily, with or ...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myeloid leukemia (CML) in adults with Philadelphia chromosome-positive (Ph+) disease, particularly in patients who are resistant or int...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC)
Adult dose: | 20 mg orally once daily, taken at the same time each day...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC)
Adult dose: | 60 mg orally once daily; may be adjusted based on tolera...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to crizotinib
Adult dose: | 4...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations
Adult dose: | 45 mg orally once daily; may be reduced to 30 mg or ...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations
Adult dose: | 30 mg orally once daily, taken continuously until di...
Class: | Topical Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe atopic dermatitis in adults and pediatric patients aged 12 years and older
Adult dose: | Apply a thin layer to ...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Adult dose: | 6 mg orally once daily...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult and pediatric patients with solid tumors that are ROS1-positive or NTRK-positive, including non-small cell lung cancer (NSCLC) and other ...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult and pediatric patients with solid tumors that are positive for NTRK gene fusions, ROS1-positive non-small cell lung cancer (NSCLC), and o...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult and pediatric patients with solid tumors that are positive for NTRK gene fusions, ROS1-positive non-small cell lung cancer (NSCLC), and o...